Luo et al. found that SGLT-2 inhibitors can decrease GV and improve the function of islet beta-cells in patients with type 2 diabetes treated with insulin in combination with other antidiabetic drugs [25]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.